Neuren Pharmaceuticals(ASX:NEU)
Developing drug therapies forserious neurological disorders that emerge in early childhood &have no or limited treatment options
Highly successful US launchof DAYBUE™ (trofinetide) for Rett syndrome by partner Acadia
2023 net sales of US$177.2m;A$27m NEU royalties
1Q24 net sales US$75.9;A$11.6m royalties
2024 net sales guidance ofUS$370-420m; would earn NEU A$61-70m + A$77m sales milestone
Acadia advancingDAYBUE™ in Canada, Europe & Japan
NNZ-2591 in Phase 2 trialsfor four syndromes; 5x Rett market
All indications received FDAinvestigational new drug (IND) & orphan drug designation
Pitt Hopkins topline resultsexpected 2Q24, Angelman results expected 3Q24
Dec'23: PMS demonstratedsignificantly positive results, preparation underway for FDA end of Ph2 meeting
$243.1m cash as of 31 Mar'24
Market cap ~ $2.58B
- Forums
- ASX - By Stock
- Neuren Media and Analyst Coverage
Neuren Pharmaceuticals(ASX:NEU)Developing drug therapies...
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.74 |
Change
-0.200(1.00%) |
Mkt cap ! $2.548B |
Open | High | Low | Value | Volume |
$19.95 | $19.95 | $19.74 | $2.491M | 124.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 108 | $19.71 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.79 | 280 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 405 | 21.930 |
2 | 15545 | 21.550 |
1 | 27738 | 21.540 |
1 | 3 | 21.520 |
1 | 87 | 21.450 |
Price($) | Vol. | No. |
---|---|---|
17.950 | 37254 | 3 |
17.960 | 1808 | 1 |
18.350 | 19425 | 1 |
18.550 | 252 | 1 |
18.950 | 4831 | 3 |
Last trade - 10.13am 20/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online